|1.||Nowotnik, David P: 3 articles (11/2009 - 04/2006)|
|2.||Howell, Stephen B: 2 articles (09/2007 - 04/2006)|
|3.||Cvitkovic, Esteban: 1 article (11/2009)|
|4.||Campone, Mario: 1 article (09/2007)|
|5.||Rademaker-Lakhai, Jeany M: 1 article (09/2007)|
|6.||Beijnen, Jos H: 1 article (09/2007)|
|7.||Schellens, Jan H M: 1 article (09/2007)|
|8.||Bennouna, Jaafar: 1 article (09/2007)|
|9.||Gerberich, Jennifer L: 1 article (04/2006)|
|10.||Rice, John R: 1 article (04/2006)|
04/01/2006 - "The goal of these studies was to determine the rate of release of Pt as a function of pH, the antitumor activity, and plasma and tumor pharmacokinetics of AP5346 in preclinical models. "
09/01/2007 - "To determine the maximum tolerated dose (MTD) safety and pharmacokinetics of AP5346, a copolymer-linked 1,2-diaminocyclohexane(DACH)-platinum compound, in advanced solid tumor patients. "
11/12/2009 - "This review summarizes the development of ProLindac to date, including preclinical efficacy studies, the phase I monotherapy clinical study in patients with solid tumors, and the phase I/II monotherapy study in patients with recurrent ovarian cancer. "
04/01/2006 - "Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system."
04/01/2006 - "AP5346 produced a marked increase in the delivery of diaminocyclohexane Pt to the tumor and tumor DNA over and above that attainable with oxaliplatin."
|2.||Ovarian Neoplasms (Ovarian Cancer)
|4.||DNA (Deoxyribonucleic Acid)